Background Rituximab (RTX) and other anti-CD20 therapies are increasingly used as
disease modifying treatments (DMTs) in MS. However, data on reasons to interrupt …

Objective: To investigate the efficacy of rituximab as rescue therapy in patients with
relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by …

Background Rituximab (RTX) is an extensively used off-label drug for multiple sclerosis
(MS), whereas the induction and maintenance regimens vary widely among studies. Few …

Background Rituximab is safe and effective for treating relapsing–remitting multiple sclerosis
(RRMS) according to phase II and observational studies. There are limited data on disease …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Objective: New disease-modifying treatment strategies in multiple sclerosis offer possibilities
for individualised treatment. In this study, we evaluated patient-reported outcome measures …

Background Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin
lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. Objectives …

Importance Comparative real-world effectiveness studies of initial disease-modifying
treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include …

Objective To describe 2 patients with relapsing-remitting multiple sclerosis (RRMS)
receiving long-term treatment with the monoclonal antibody rituximab. The clinical and …

Objective: B cells and the humoral immune system have been implicated in the
pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety …